Drugmaker Morepen Laboratories said its ₹325-crore formulation business was targeting ₹1,000 crore in five years, on the back of local and global sales.

The growth would be driven by “deeper market penetration, an expanded field force and a growing portfolio of cost-efficient, globally-compliant therapies,” the company said. Its stock price soared on the development, ending the day up over 14 per cent at ₹62.20, on BSE, Thursday.

New launches

The company also said it had launched four new products — Ticapen, UdoFix, LycoMore and Acifix — in the domestic market, besides Empamore last month. The new launches reflect Morepen’s research-led products in cardiology, hepatology, nutrition and diabetology, it said.

This expansion reinforced Morepen’s finished dosages (formulations) business while continuing to invest in research to drive a pipeline of differentiated medicines, it said. The active pharmaceutical ingredients (APIs) used in these products are also manufactured in-house by Morepen at USFDA-approved plants, it added.

The company also said it was a leading API exporter for six globally-used molecules— Loratadine, Montelukast, Desloratadine, Atorvastatin, Rosuvastatin and Fexofenadine. It had presence in 82 countries, backed by an annual API manufacturing capacity of 144 metric tonnes, it added. Its integrated capabilities across the pharmaceutical value chain give it a competitive edge across regulated and emerging markets, it said.

Published on April 24, 2025